Accurate Fertility Detector Introduced

By LabMedica International staff writers
Posted on 05 Nov 2013

A fertility-monitoring detector has been launched in the market for use in the US. The device, called OvuSense, was cleared by the US Food and Drug Association (FDA; Silver Spring, MD, USA).

OvuSense was launched by Fertility Focus (The Woodlands, TX, USA) and Norgenix Pharmaceuticals (Spartanburg, SC, USA). The device delivers 99% sensitivity and 99% accuracy, making it the most precise fertility detector in the market. OvuSense predicts the onset of ovulation, detects the exact ovulation date just three days after it occurs, and provides all this information in real time on the screen to the user. This level performance, for the first time, puts the certainty of ultrasound in a handheld ovulation monitor. Fertility Focus presented OvuSense at the American Society of Reproductive Medicine (ASRM) Conference which was held in Boston (MA, USA), in October 2013.

Image: OvuSense an accurate fertility detector is an advanced ovulation monitor that delivers 99% sensitivity and 99% accuracy, making it the most precise in the market (Photo courtesy of Norgenix Pharmaceuticals).

"We are pleased to announce our partnership with Fertility Focus," stated Michael Rackley, COO and senior vice president of Norgenix Pharmaceuticals, LLC. "Fertility Focus's OvuSense device is an innovative product that perfectly aligns with our strategic mission to offer solutions to unmet needs in women's health. We are very optimistic about the potential for OvuSense, and we expect to expand the market rapidly."

Related Links:
US Food and Drug Association
Fertility Focus
Norgenix Pharmaceuticals